

ERRATUM

Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J study

Takao Saruta, Koichi Hayashi, Toshio Ogihara, Kazuwa Nakao, Tsuguya Fukui and Kohshiro Fukiyama, for the CASE-J Study Group

Hypertension Research (2009) **32**, 1157; doi:10.1038/hr.2009.181

Correction to: *Hypertension Research* (2009) **32**, 505–512; doi: 10.1038/hr.2009.44 apologize for this and are now happy to correct this mistake. The correct table is shown below:

During typesetting and correction of the above paper, Stage 3 was applied twice in Table 3 and published as such. The publishers

Table 3 Comparison of composite cardiovascular end point and each cardiovascular event in various CKD stages

	Candesartan (n=172)	Amlodipine (n=158)	HR (95% CI)	P
Stage 1+2				
Cardiovascular events	18 (10.5%)	13 (8.2%)	1.243 (0.609–2.537)	0.551
Cerebrovascular events	11 (6.4%)	7 (4.4%)	1.402 (0.544–3.618)	0.484
Cardiac events	1 (0.6%)	4 (2.5%)	0.221 (0.025–1.978)	0.177
Renal events	2 (1.2%)	3 (1.9%)	0.604 (0.101–3.616)	0.581
Stage 3				
Cardiovascular events	72 (6.3%)	71 (6.3%)	1.006 (0.725–1.396)	0.972
Cerebrovascular events	32 (2.8%)	29 (2.6%)	1.095 (0.663–1.810)	0.723
Cardiac events	26 (2.3%)	27 (2.4%)	0.946 (0.552–2.622)	0.841
Renal events	14 (1.2%)	9 (0.8%)	1.532 (0.663–3.540)	0.318
Stage 4				
Cardiovascular events	9 (14.1%)	18 (29.5%)	0.446 (0.200–0.995)	0.048
Cerebrovascular events	1 (1.6%)	4 (6.6%)	0.235 (0.026–2.106)	0.196
Cardiac events	3 (4.7%)	1 (1.6%)	3.060 (0.318–29.458)	0.333
Renal events	3 (4.7%)	14 (23.0%)	0.185 (0.053–0.644)	0.008